Zymeworks Inc. Common Shares (ZYME): Price and Financial Metrics


Zymeworks Inc. Common Shares (ZYME)

Today's Latest Price: $39.12 USD

0.86 (-2.15%)

Updated Oct 30 7:00pm

Add ZYME to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

ZYME Stock Summary

  • ZYME's price/sales ratio is 58.78; that's higher than the P/S ratio of 96.28% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Zymeworks Inc is reporting a growth rate of 242.97%; that's higher than 94.23% of US stocks.
  • Revenue growth over the past 12 months for Zymeworks Inc comes in at -40.21%, a number that bests just 6.29% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Zymeworks Inc, a group of peers worth examining would be CLLS, CUE, ARVN, APTX, and ACRS.
  • ZYME's SEC filings can be seen here. And to visit Zymeworks Inc's official web site, go to www.zymeworks.com.

ZYME Stock Price Chart Interactive Chart >

Price chart for ZYME

ZYME Price/Volume Stats

Current price $39.12 52-week high $52.75
Prev. close $39.98 52-week low $20.33
Day low $38.30 Volume 250,715
Day high $40.31 Avg. volume 441,676
50-day MA $40.15 Dividend yield N/A
200-day MA $37.55 Market Cap 1.78B

Zymeworks Inc. Common Shares (ZYME) Company Bio


Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company was founded in 2003 and is based in Vancouver, BC.


ZYME Latest News Stream


Event/Time News Detail
Loading, please wait...

ZYME Latest Social Stream


Loading social stream, please wait...

View Full ZYME Social Stream

Latest ZYME News From Around the Web

Below are the latest news stories about Zymeworks Inc that investors may wish to consider to help them evaluate ZYME as an investment opportunity.

Zymeworks to Present at Upcoming Investor Conferences

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will participate in three upcoming virtual investor conferences. Wells Fargo’s 2020 Healthcare Conference is scheduled for September 9-10, 2020. Zymeworks is presenting on Wednesday, September 9, 2020 at 11:20 a.m. ET. Citi’s 15th Annual BioPharma Conference is scheduled for September 9-10, 2020. H.C. Wa

Business Wire | September 3, 2020

Zymeworks Reports 2020 Second Quarter Financial Results

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the quarter ended June 30, 2020. “Among many notable accomplishments in the past quarter, I am particularly excited about the transition of our lead therapeutic program, zanidatamab, into late stage clinical development, providing a clear path for Zymeworks to seek its first potential approval in bi

Business Wire | August 5, 2020

Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 31, 2020

Did Hedge Funds Make The Right Call On Zymeworks Inc. (ZYME) ?

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

Yahoo | July 12, 2020

Zymeworks Corporate Update Webcast and Conference Call Summary

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today hosted a webcast and conference call highlighting its progress and key accomplishments in the first half of 2020. “I’m proud to say we’ve taken a major step towards achieving our goal of bringing an important new therapeutic to patients with HER2-expressing cancers,” said Ali Tehrani, Ph.D., President and CEO of Zymeworks. “ZW25,

Business Wire | July 8, 2020

Read More 'ZYME' Stories Here

ZYME Price Returns

1-mo -15.12%
3-mo 28.14%
6-mo 9.92%
1-year 11.74%
3-year 385.36%
5-year N/A
YTD -13.95%
2019 209.67%
2018 93.41%
2017 N/A
2016 N/A
2015 N/A

Continue Researching ZYME

Here are a few links from around the web to help you further your research on Zymeworks Inc's stock as an investment opportunity:

Zymeworks Inc (ZYME) Stock Price | Nasdaq
Zymeworks Inc (ZYME) Stock Quote, History and News - Yahoo Finance
Zymeworks Inc (ZYME) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7395 seconds.